Navigation Links
GENova appoints Dr. Anders Boegh Jensen to Scientific Advisory Board
Date:9/8/2009

NEW YORK, NY, Sept. 8 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotheropeutics, Inc., ("GENova"), a biotechnology company that identifies, acquires, and develops novel drug targets that disrupt the advance of life-threatening diseases, today announced it has appointed Dr. Anders Boegh Jensen to its Scientific Advisory Board (SAB).

Dr. Boegh Jensen will contribute his considerable expertise in biotechnology and molecular biology to GENova's business of identifying, evaluating and developing pioneering research drugs. His expertise is acknowledged by companies such as Pfizer, Amgen, Myriad Genetics, Medarex, and Biogen Idec.

Aaron Whiteman, CEO of GENova, says, "We are delighted to have Mr. Boegh Jensen join the SAB. His credentials and experience in the biotech field will be an asset to GENova as we continue to identify promising cancer-fighting drug patents."

Anders Boegh Jensen, Ph.D.

Anders Boegh Jensen is a biochemist who specializes in biotechnology, genetics and molecular biology. He is currently the Director at Poalis, a plant-based biotechnology company, and serves as an Industrial Representative Board Member at the Danish Society for Biochemistry and Molecular Biology. Dr. Boegh Jensen is also frequently published in leading industry journals such as "Cell". His previous position was Associate Professor at the Institute of Molecular Biology at the University of Copenhagen where he helped modernize biology education and developed advanced Ph.D. courses.

Anders Boegh Jensen's academic credentials include: completion of a Master's thesis at the Institute of Molecular Biology, University of Copenhagen in 1989; a one-year research term at the Carlsberg Research Laboratory; and being awarded a four-year European Union BRIDGE mobility fellowship for his post-graduate research training at the Dept. of Plant Molecular Genetics, CID, CSIC, Barcelona, Spain. He completed his Ph.D thesis in Molecular Biology and Genetics in 1994.

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies.

Forward Looking Statements

This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.


'/>"/>
SOURCE GENova Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Genova files patent for new prostate cancer treatment
2. GENova names Dr. John Savin as Vice President
3. GENova names Aaron Whiteman as CEO
4. Allscripts to Announce Fiscal First Quarter Results on September 29, 2009; Company Appoints Vice President of Investor Relations
5. KV Pharmaceutical Appoints Interim Chief Financial Officer
6. Rib-X Pharmaceuticals, Inc. Appoints Tom Kassberg Chief Business Officer
7. Mindray DS USA Appoints Michael Thompson Vice President of U.S. Ultrasound Sales
8. XLHealth Appoints New Controller to Lead Financial Compliance, Accounting Initiatives
9. IMIA Interpreter Association Appoints Brazil Representative
10. HCA Appoints Dr. Richard Tayrien Chief Health Information Officer
11. SCOLR Pharma, Inc. Appoints Stephen J. Turner as CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Medical Market Analysis 2016 - Forecast to 2022" report ... The report contains up to date financial data derived from ... of major trends with potential impact on the market during ... market segmentation which comprises of sub markets, regional and country ...
(Date:6/23/2016)... June 23, 2016 Bracket , a leading ... next generation clinical outcomes platform, Bracket eCOA (SM) 6.0, ... June 26 – 30, 2016 in Philadelphia ... Clinical Outcome Assessment product of its kind to fully integrate ... Bracket eCOA 6.0 is a flexible platform for electronic ...
(Date:6/23/2016)... -- Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas is ...
Breaking Medicine Technology: